US Continues to Push Demand for Depression Drugs Market

Fact.MR analysis the global depression drugs market for the forecast period 2018 – 2026. The exhaustive study is aimed at recognizing lucrative opportunities available in the global depression drugs market. The study offers updates and insights into various categories of the depression drugs market. The comprehensive study begins with a detailed overview of the depression drugs market, which assesses the market performance in terms of revenue, key trends, restraints, and drivers prevailing in the global depression drugs market.

Request Free Sample Report Here:

https://www.factmr.com/connectus/sample?flag=S&rep_id=3215

According to the World Health Organization (WHO), depression has become one of the common illnesses, affecting over 300 million people across the world. In the United States, approximately 10.3 million adults had experienced at least one major depressive episode that resulted in severe impairment, according to the National Institute of Mental Health (NIMH). High prevalence of such depressive episode was observed among people aged 18-25 (10.9%), female adults (8.5%), and male adults (4.8%). According to the Fact.MR study, although depression continues to be a major health issue, medical community and patients are encouraging a non-drug approach to reduce side effects and dependency.

Fact.MR offers accurate data depending on supply side, demand side, and dynamics of the global depression drugs market. This comprehensive study encompasses market forecast in terms of revenue (US$ Mn). This in-depth study also offers stats on Year-on-Year (Y-o-Y) growth of the depression drugs market. Key information about the depression drugs market share is drawn through regional pricing trends. Market size and forecast for each section have been incorporated in terms of the global and regional depression drugs markets. The market has been weighed based on the robust demand determinants. The values used for calculating the market size are obtained through primary researches carried out by setting up interviews with a number of manufacturers, distributors, and suppliers of the depression drugs market.

Depression Drugs Market: Segment-wise Insights

  • On the basis of drug class, the global depression drugs market has been segmented into SSRIs, atypical antipsychotics, SNRIs, CNS stimulants, and others. Of these, atypical antipsychotics is expected to contribute the largest share in the market.
  • Major depressive disorder has been envisaged to account for the most substantial share in the depression drugs market based on disease type. Other sub-segments include SSRI induced, schizophrenia, and bipolar I disorder.
  • While depression drugs are sold across retail, hospital, and online pharmacies, the retail segment registered the largest share in 2017, and the trend is expected to continue during the 2018-2026 period.

 Global Depression Drugs Market: Competitive Landscape

Some key players operating in the manufacturing of depression drugs are Otsuka Pharmaceutical Co., Ltd., Johnson & Johnson, Sebela Pharmaceutical Inc., GlaxoSmithKline plc, AstraZeneca plc, Eli Lilly and Company, Allergan USA, Inc., Takeda Pharmaceutical Company Ltd, Novartis AG, Pfizer, Inc., Alkermes Plc, H. Lundbeck, Bristol Myers Squibb Co., and Teva Pharmaceutical Industries Ltd.

Browse Full report on  Market with TOC:

https://www.factmr.com/report/3215/depression-drugs-market

 

Leave a Reply

Your email address will not be published. Required fields are marked *